EJHaem · 2024
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madero-Marroquin Rafael, Hunter Ryan W, Saygin Caner, Johnston Hannah, DuVall Adam S, Rahmani Youshanlouei Hamed, Osei Clinton, Shah Syed, Stock Wendy, Gurbuxani Sandeep, Patel Anand A
Аннотация
BACKGROUND: CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.
METHODS: Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).
RESULTS: The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.
CONCLUSION: Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.
METHODS: Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).
RESULTS: The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.
CONCLUSION: Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.